Detalhe da pesquisa
1.
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
J Med Virol
; 95(1): e28157, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117402
2.
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Br J Cancer
; 125(4): 582-592, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34088988
3.
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes.
Eur J Haematol
; 107(5): 553-565, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289175
4.
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
J Cell Mol Med
; 24(5): 2968-2980, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31967735
5.
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
J Cell Mol Med
; 24(3): 2145-2156, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943762
6.
Inhibition of the deubiquitinase USP10 induces degradation of SYK.
Br J Cancer
; 122(8): 1175-1184, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32015510
7.
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Pharm Res
; 37(9): 167, 2020 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32778962
8.
Current therapies under investigation for COVID-19: potential COVID-19 treatments.
Can J Physiol Pharmacol
; 98(8): 483-489, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640179
9.
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Br J Haematol
; 187(4): 488-501, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31309543
10.
Inhibition of USP10 induces degradation of oncogenic FLT3.
Nat Chem Biol
; 13(12): 1207-1215, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28967922
11.
Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.
Eur J Haematol
; 102(4): 341-350, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578743
12.
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
Blood
; 125(20): 3133-43, 2015 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25833960
13.
Structure-guided development of covalent TAK1 inhibitors.
Bioorg Med Chem
; 25(3): 838-846, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28011204
14.
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Bioorg Med Chem
; 25(4): 1320-1328, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28038940
15.
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.
Blood
; 123(18): 2816-25, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24574459
16.
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Nat Rev Cancer
; 7(5): 345-56, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17457302
17.
Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells.
BMC Cancer
; 15: 803, 2015 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26503699
18.
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Cancer Cell
; 12(6): 501-13, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18068628
19.
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.
Arch Toxicol
; 88(12): 2233-42, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25331939
20.
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.
Cancers (Basel)
; 16(7)2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38610997